MF: C32H47F5O3S
MW: 606.77
mp 104-106°C
storage temp. 2-8°C
Chemical Properties White Powder
Usage A novel steroidal estrogen antagonist reported to lack any partial agonist activity. Antineoplastic (hormonal).
Usage Antiestrogen
Biological Activity A high affinity estrogen receptor antagonist (IC 50 = 0.29 nM), devoid of any partial agonism both in vitro and in vivo . Also high affinity agonist at the membrane estrogen receptor GPR30.
Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Nuclear Receptors;Chiral Reagents;Steroids;Sulfur & Selenium Compounds;FASLODEX;Anti-cancer&immunity
Synonyms: ICI 182,780;;-13C1-D2;FASLODEX;(7a,17b)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol;7A,17B-[9[(4,4,5,5,5-PENTAFLUOROPENTYL)SULFINYL]NONYL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL;(7alpha,17beta)-nonyl);estra-1,3,5(10)-triene-3,17-diol,7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)
Description:
Fulvestrant Acetate (trade name Faslodex, by Astra Zeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is a completeestrogen receptor antagonist with no agonist effects, which in addition, accelerates the proteasomal degradation of the estrogen receptor. The drug has poor oral bioavailability, and is administered monthly via intramuscular injection.
China
